Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences

Aldeyra Therapeutics, Inc. ALDX (Aldeyra) today announced that senior management will be presenting and hosting 1x1 meetings at the following virtual investor conferences in August:

• BTIG Virtual Biotechnology Conference 2020
  Presentation Date: Tuesday, August 11, 2020
  Time: 11:30 a.m. ET

• 2020 Wedbush PacGrow Healthcare Virtual Conference
  Presentation Date: Wednesday, August 12, 2020
  Time: 12:35 p.m. ET

A live webcast of these presentations will be available on the investor relations page of the company's corporate website at https://ir.aldeyra.com. After the live webcast, the events will remain archived on the Aldeyra Therapeutics website for 90 days.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200804005249/en/